ClinicalTrials.gg
CompletedNCT03043521Updated Feb 6, 2017

Pharmacodynamic Properties of CJ-12420 on Evening Dosing

A Phase 1 interventional study of Dexlansoprazole 60 MG and CJ-12420 50mg in Healthy, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-06.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled May 2015, registered Jan 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to compare and evaluate impact on pharmacodynamic characteristics of CJ-12420 and dexlansoprazole with evening dosing in healthy male volunteers

Read the detailed description

Evaluation Criteria:

  1. Pharmacokinetic Endpoints Cmax, tmax, AUClast of CJ-12420
  2. Pharmacodynamics Endpoints Time pH > 4 Time pH > 6 Integrated acidity Percent inhibition of integrated acidity Percent inhibition time gastric pH ≤ 4 Median pH
  3. Safety Assessments Physical examination, ECGs, vital signs (blood pressure, heart rate, body temperature), laboratory test (CBC, Chemistry, UA), and adverse events (AEs)
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male volunteers aged ≥20 to ≤45 years
  2. (BMI) of 19 to 28kg/m2 ; and a total body weight ≥ 50kg
  3. Medically healthy without vital signs (blood pressure in sitting position, heart rate)

    • 90 mmHg ≤ Systolic blood pressure (SBP) ≤ 140 mmHg
    • 50 mmHg ≤ Diastolic blood pressure (DBP) ≤ 95 mmHg
    • 45 (beats/min) ≤ Heart rate ≤ 95 (beats/min)
  4. Understand restriction during the study and voluntarily consent to participate in the study
  5. Consent to use the effective methods (using abstinence, spermicide, and condom) and not to donate sperm during the study and until 30 days after completion of study
  6. Non-smoker or ex-smoker who stopped smoking for at least one year
  7. Negative H. pylori result in urea breath test (UBT)

Exclusion criteria

Exclusion Criteria:

  1. History of diseases in the digestive, kidney, liver, nervous, hemato-oncologic, endocrine, respiratory, immune, psychiatric, musculoskeletal, or cardiovascular system and other diseases that may harm safety of the subject or may affect the validity of study results, in the judgment of investigator
  2. History of allergy or to any drugs including serious adverse events from treatments such as PPI (omeprazole, rabeprazole, lansoprazole) or P-CAB
  3. History surgery that may affect absorption, distribution, metabolism, and elimination of the study drug or in such a medical condition, at the discretion of the principal investigator or sub-investigator
  4. History of use of another product within 90 days prior to screening visit
  5. Donation of a unit of whole blood within 60 days or blood components or transfusion within 30 days prior to screening visit
  6. Having special diet or changes in dietary habits within 30 days prior to screening visit
  7. Use of prescription drug within 14 days or over-the-count (OTC) drug including herbal medicine within 7 days prior to screening visit
  8. Alcohol > 21 units/week
  9. Caffeinated drink intake > 5units/day
  10. Positive on urinary drug screening test or urine nicotine test
  11. Positive (HIV), , , or syphilis test
  12. Clinically significant abnormal result of liver function (serum , AST or total levels ≥ 1.5 times the (ULN))
  13. Inability to tolerate pH catheter insertion
  14. History of symptomatic GERD, erosive esophagitis (EE), duodenal ulcer, gastric ulcer, Barrett's esophagus, or Zollinger-Ellison Syndrome
  15. Any other conditions which would have made the subject unsuitable for the study in the opinion of the investigator
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    CJ-12420 50mg

    T1=CJ-12420 50mg QD evening (9PM)

    Drug: CJ-12420 50mg

  • Experimental
    CJ-12420 100mg

    T2=CJ-12420 100mg QD evening (9PM)

    Drug: CJ-12420 100mg

  • Experimental
    CJ-12420 200mg

    T3=CJ-12420 200mg QD evening (9PM)

    Drug: CJ-12420 200mg

  • Active comparator
    Dexlansopazole 60mg

    R=dexlansoprazole 60mg QD evening (9p.m)

    Drug: Dexlansoprazole 60 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Time pH > 4 of CJ-12420

    intragastric pH

    Time frame: 24 hours pH

Secondary outcomes

  1. Cmax of CJ-12420

    maximum measured plasma concentraion

    Time frame: up to 20 hours

  2. AUClast of CJ-12420

    The area under the plasma concentration versus time curve from time 0 to the last measurable concentration

    Time frame: up to 20 hours

  3. Cmax of dexlansoprazole

    maximum measured plasma concentraion

    Time frame: up to 20 hours

  4. AUClast of dexlansoprazole

    The area under the plasma concentration versus time curve from time 0 to the last measurable concentration

    Time frame: up to 20 hours

  5. Time pH > 4 of dexlansoprazole

    intragastric pH

    Time frame: 24 hours pH

  6. Median pH > 4 of CJ-12420

    intragastric pH

    Time frame: 24 hours pH

  7. Median pH > 4 of dexlansoprazole

    intragastric pH

    Time frame: 24 hours pH

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2015 to primary completion in Aug 2015, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2017
First posted
Feb 6, 2017
StartActual
May 13, 2015
Primary completionActual
Aug 12, 2015
CompletionActual
Aug 12, 2015
Last update
Feb 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03043521
Responsible party
Sponsor
First posted
Feb 6, 2017
Start date
May 13, 2015
Primary completion
Aug 12, 2015
Completion
Aug 12, 2015
Last update
Feb 6, 2017

Study contacts

Eunji Kim
study director · CJ HealthCare Corp.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion